XML 49 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
Organization and Basis of Presentation - Narrative (Detail) - USD ($)
12 Months Ended
Oct. 24, 2014
May 16, 2014
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Principles of Consolidation    
The accompanying consolidated financial statements include the accounts of Zogenix, Inc. and its wholly owned subsidiary Zogenix Europe, which was incorporated under the laws of England and Wales in June 2010. Also included is Zogenix International Limited, a wholly owned subsidiary of Zogenix Europe. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.
   
Common stock, shares authorized     50,000,000 50,000,000  
Business Acquisition [Line Items]          
Principal balance outstanding     $ 20,000,000    
Proceeds from divestiture of businesses     $ 0 $ 82,984,000 $ 89,624,000
Brabant Pharma Limited [Member]          
Business Acquisition [Line Items]          
Aggregate amount of contingent liabilities $ 95,000,000        
Brabant Pharma Limited [Member] | Regulatory Milestones [Member]          
Business Acquisition [Line Items]          
Aggregate amount of contingent liabilities 50,000,000        
Brabant Pharma Limited [Member] | Sales Milestones [Member]          
Business Acquisition [Line Items]          
Aggregate amount of contingent liabilities $ 45,000,000        
Notes Payable, Other Payables [Member]          
Business Acquisition [Line Items]          
Principal balance outstanding   $ 7,000,000      
Sumavel DosePro [Member]          
Business Acquisition [Line Items]          
Proceeds from divestiture of businesses   85,000,000      
Escrow deposit   8,500,000      
Net product revenue   $ 4,624,000